PRM34 - Cost –Effectiveness of Obinutuzumab As Frontline Treatment For Unfit Patients With Chronic Lymphocytic Leukemia In Republic of Macedonia.

Autor:	Kapedanovska Nestorovska, A1, Sterjev, Z1, Naumovska, Z1, Grozdanova, A1, Dimovski, A1, Suturkova, L1
Zdroj:	Value in Health. Oct2017, Vol. 20 Issue 9, pA736-A736. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect